The NHS is "leading the world" and is currently on track to eliminate Hepatitis C in England by 2025 due a pioneering drug deal and a strong effort to find those at risk.
A five-year contract worth almost £1 billion to buy antiviral drugs for patients has seen deaths from Hepatitis C – including liver disease and cancer – fall by 35%, leading NHS England to be five years ahead of global targets which were set at 10 per cent.
Dedicated “Find And Treat” programmes have also been a factor in the drive to cut deaths caused by Hepatitis C, with vulnerable communities such as the homeless now being treated.
Hepatitis C is a blood-borne virus which, left untreated, can cause liver cancer and liver failure.
It usually displays no symptoms until the virus causes enough damage to bring on liver disease. Symptoms may include fatigue and difficulty concentrating and the virus is also linked to cardiovascular disease, mental health issues, kidney disease and musculoskeletal pain.
Effective antiviral drugs can cure more than 95% of people with minimal side effects, which means it can be eliminated.
Professor Sir Stephen Powis, NHS England’s national medical director, said the NHS is "leading the world" in the drive to save lives and eliminate Hepatitis C while also tackling a "significant" health inequality.
He said: "Thanks to targeted screening and because the NHS has a proven track record of striking medicine agreements that give patients access to the latest drugs, we are on track to beat global targets and become the first country to eliminate Hepatitis C by 2030 – which will be a landmark achievement."
St Mungo’s is one of the charities behind the Find And Treat outreach programmes which aim to ensure no one, including those historically hard to reach and treat, is left behind in the fight against Hepatitis C. It has seen specialist teams provide same-day screenings along with help to complete a full course of treatment.
Substance use, sharing toothbrushes, razors and other general lifestyle factors associated with sleeping rough are among a range of reasons putting the homeless at a higher risk of contracting Hepatitis C.
Sara Hide, a Hepatitis C co-ordinator at St Mungo’s in Oxford, said: "With treatment for Hepatitis C now less invasive – a course of medication for eight to 12 weeks – we’ve seen an uptake in people responding to our screening services. We also screen for other conditions at the same time to identify clients that might need extra health support."
The project has helped find and cure 70,000 people of the potentially fatal disease and reduced the number of people seeking liver transplants due to Hepatitis C, NHS England said. Within six years, the number of people seeking liver transplants due to the virus fell by two-thirds and the number of annual registrations for a liver transplant in patients with Hepatitis C-related diseases dropped from fewer than 140 per year to fewer than 50 per year in 2020.
The project has also provided 80% of its treatments to people from communities in the poorest half of the population. An NHS screening programme launched in September is enabling thousands of people unknowingly living with Hepatitis C to get a diagnosis and treatment sooner by searching health records for key risk factors, such as historic blood transfusions or those with HIV.
Hepatitis C Trust chief executive Rachel Halford said the charity is "delighted to be a part of this unique elimination deal" to help find, test and treat people most at risk of contracting hepatitis C.
She said: "The progress that has been made towards elimination is truly astounding. We now need a final concerted effort to make sure we reach all those that may be affected and reach elimination. Investment in a national campaign to improve public awareness of hepatitis C to reduce stigma and encourage people who may have been at risk to get tested is paramount."
